X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This second tranche is in connection with the Company’s successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully human anti-LIGHT monoclonal antibody for moderate- to-severe Crohn's disease.
Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Gastroenterology Product Name: CERC-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 02, 2021
Details:
The study is a pilot study using a dose-escalation design to characterize the safety and tolerability of two different doses of CERC-002 (1.0 mg/kg and 3.0 mg/kg).
Lead Product(s): AEVI-002
Therapeutic Area: Gastroenterology Product Name: CERC-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14).
Lead Product(s): AEVI-002
Therapeutic Area: Infections and Infectious Diseases Product Name: CERC-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). IL-18 has been demonstrated to have a key role as a marker of disease activity and its concentration correlates with disease severity in AOSD patients.
Lead Product(s): AEVI-007
Therapeutic Area: Immunology Product Name: CERC-007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphocytes.
Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CERC-002
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Kyowa Kirin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 29, 2021
Details:
COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo.
Lead Product(s): CERC-002
Therapeutic Area: Infections and Infectious Diseases Product Name: AEVI-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
This trial will study the safety, tolerability, and efficacy of CERC-801 in patients with PGM1-CDG using daily therapeutic doses of CERC-801 in approximately ten patients.
Lead Product(s): Alpha-D-Galactose
Therapeutic Area: Genetic Disease Product Name: CERC-801
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: CDG Care
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2020
Details:
Cerecor has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic.
Lead Product(s): CERC-002
Therapeutic Area: Gastroenterology Product Name: AEVI-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
Publication supports Cerecor clinical program evaluating CERC-002, the only clinical stage anti-LIGHT monoclonal antibody, as a potential treatment for patients with severe COVID-19 acute respiratory distress syndrome.
Lead Product(s): CERC-002
Therapeutic Area: Infections and Infectious Diseases Product Name: AEVI-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations (LM).
Lead Product(s): CERC-006
Therapeutic Area: Rare Diseases and Disorders Product Name: CERC-006
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Calidi Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
